Skip to main content
NCBI home page
BioMed Research International logoLink to BioMed Research International
. 2022 Jul 11;2022:2399888. doi: 10.1155/2022/2399888

Maternal Smoking and the Risk of Placenta Accreta Spectrum: A Systematic Review and Meta-Analysis

Ensiyeh Jenabi 1, Amir Mohammad Salehi 2,✉, Seyedeh Zahra Masoumi 3, Azam Maleki 4
PMCID: PMC9293521  PMID: 35860796

Abstract

Background

This is the first meta-analysis that assessed the association between maternal smoking and the risk of placenta accreta spectrum (PAS), so this study was aimed at investigating the association between maternal smoking and PAS based on observational studies. PAS is defined as a severe obstetric complication due to the abnormal invasion of the chorionic villi into the myometrium and uterine serosa.

Methods

We searched electronic bibliographic databases including PubMed, Web of Science, Scopus, Science Direct, and Google Scholar until January 2022. The results were reported using a random effect model. The chi-square test and the I2 statistic were used to assess heterogeneity. Egger's and Begg's tests were used to examine the probability of publication bias. All statistical analyses were performed at a significance level of 0.05 using Stata software, version 11.

Results

Based on the random effect model, the estimated OR of the risk of PAS associated with smoking was 1.21 (95% CI: 1.02, 1.41; I2 = 4.7%). Subgroup analysis was conducted based on study design, and the result showed that the association between smoking and PAS among cohort studies was significant 1.35 (95% CI: 1.15, 1.55; I2 = 0.0%).

Conclusion

Our results suggested that maternal smoking is a risk factor for the PAS. There was no heterogeneity among studies that reported an association between smoking and the PAS. The Newcastle-Ottawa Scale (NOS) was used to measure study quality.

1. Introduction

Placenta accreta spectrum (PAS), formerly known as adherent placenta, is a term used to describe the abnormal attachment of placental trophoblasts to the uterine myometrium and includes placenta accreta (placenta attachment to myometrium without decidua intervention), increta placenta (trophoblast invasion to myometrium), and percreta placenta (invasion through the myometrium is serous and into the surrounding structures) [1].

The importance of this disease is due to the increase in maternal and fetal mortality. Fetal outcomes are mainly due to iatrogenic prematurity, while maternal outcomes are mainly due to increased risk of postpartum hemorrhage and surgical complications. The average blood loss is 3000-5000 ml, and up to 90% of patients need a blood transfusion [2]. Complications of surgery include hysterectomy and injury to the ureter, bladder, and intestines, which leads to more intensive care admissions and longer hospital stays, as well as posttraumatic stress disorder (PTSD) and more psychological consequences [3].

Diagnosis of the PAS is based on two main clinical and pathological criteria. After delivery, the placenta usually separates spontaneously, and any difficulty in separating the placenta or the need for placental abruption is considered a clinical criterion for the PAS. Another clinical criterion is uncontrollable bleeding from the placenta after delivery or cesarean section [4]. Prenatal diagnosis of PAS is usually made by ultrasound [5, 6].

In the umbrella review of Jenabi et al., multiple gestation and in vitro fertilization (IVF) were identified as definitive risk factors [7]; also, in other studies, uterine surgery, placenta previa, and advanced maternal age have been introduced as risk factors [8–10]. Recently, several studies have warned about the dangers of smoking, diet, and chronic condition and their association with PAS.

The role of smoking in some diseases is also known such as esophageal cancer [11] and hypertension [12], placenta previa [13], and placenta abruption [14]; however, no meta-analysis study has quantitatively assessed the association between maternal smoking and the risk of PAS, so this study was aimed at investigating the association between maternal smoking and PAS based on observational studies. Herein, we performed the first meta-analysis to identify role association between maternal smoking and PAS.

2. Methods

The checklist of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used for performing the present meta-analysis. Investigating the association between maternal smoking and risk of PAS was performed regarding to the following PICO framework:

  1. Population: pregnant women

  2. Intervention: smoking before and during pregnancy

  3. Comparison: without smoking before and during pregnancy

  4. Outcome: risk of placenta accreta spectrum

Observational studies (case-control and cohort) reporting the association between smoking and the risk of PAS were reviewed, irrespective of language, maternal age, race, country, date, and place of publication.

The search strategy was based on combining a set of keywords (“placenta accreta” or “placenta increta” or “placenta percreta” or “placenta accreta spectrum” or “morbidly adherent placenta” or “abnormally invasive placenta”) and (“Smoking” or “cigarette” or “tobacco” or “cigar”). We searched electronic bibliographic databases including PubMed, Web of Science, Scopus, Science Direct, and Google Scholar until January 2022. To find additional references, we screened the reference lists of the included studies. In addition, we contacted authors of the studies to earn eligible studies, and conference databases were searched.

Two authors independently reviewed the articles to ensure that they met the meta-analysis inclusion criteria. Any disagreements among the authors were resolved by discussion. The two authors extracted information from the included articles. The information was the first author's name (year), country, study design, age (year), sample size, and the effect measure and its 95% confidence interval (CI). The Newcastle-Ottawa Scale (NOS) was used to measure study quality [15]. A study had a maximum of 9 NOS stars: 4 stars for quality of selection, 2 stars for comparability, and 3 stars for quality of exposures. Studies with NOS scores of 7 and higher were categorized as high quality, while studies with NOS scores of 6 and less were categorized as low quality.

The chi-square test and the I2 statistic were used to assess heterogeneity [16]. Egger's [17] and Begg's [18] tests were used to examine the probability of publication bias.

Odds ratio (OR), with their associated 95% CIs, were applied to present the measures of association between maternal smoking and PAS. We used the adjusted forms of the ORs, controlling for at least one of the potential confounding factors. The results were reported using a random effect model. We conduct a subgroup analysis based on study design and crude/adjust form. All statistical analyses were performed at a significance level of 0.05 using Stata software, version 11 (StataCorp, College Station, Texas, USA).

3. Results

3.1. Description of Studies

Until 30 January 2022, 321 studies were included in the present meta-analysis. Of these, 176 were excluded due to duplication and 145 studies remained for assessing title and abstract. Then, 128 studies were excluded after reading titles and abstracts. In total, 17 studies were remained for reading the full papers. Three full papers were not considered to be eligible (four studies were reviewed and three studies had no inclusion criteria). In the end, 14 studies were included in the current meta-analysis (Figure 1). We identified ten studies with cohort [3, 19–27] and four studies [28–31] with case-control designs. The participants in this study were 3,892,832. All studies were in English (Table 1).

Figure 1.

Figure 1

Open in a new tab

Flow of diagram of the systematic process.

Table 1.

Characteristics of the studies in the meta-analysis.

1st aut, year Design Sample Diagnose method Maternal age (year) Estimate Adjustment Quality
Usta, 2005 [28] Case-control 347 By maternal–fetal medicine physicians 31 Odds ratio Adjust High
Matsuzaki, 2021 [22] Cohort 2727477 ICD-10 codes Not reported Odds ratio Adjust High
Svanvik, 2021 [21] Cohort 9376 Attending obstetrician and clinical diagnosis Not reported Odds ratio Crude High
Kyozuka, 2019 [3] Cohort 90554 Histological examination or the clinical presentation 31.8 Odds ratio Adjust High
Wang, 2020 [19] Cohort 177 Histological 30.22 Odds ratio Crude High
Bowman, 2014 [25] Cohort 2749 Pathology or clinical findings 30.85 Odds ratio Adjust High
Tsuji, 2019 [20] Cohort 16019 Medical record 32.7 Odds ratio Crude High
Eshkoli, 2013 [24] Cohort 34869 Clinical Not reported Odds ratio Crude High
Farquhar, 2017 [29] Case-control 865 Imaging or by pathological Not reported Odds ratio Adjust High
Jauniaux, 2019 [23] Cohort 292 By physicians and ultrasound 34.30 Odds ratio Crude High
Upson, 2013 [26] Cohort 403602 ICD-10 Not reported Odds ratio Crude Low
Klar, 2013 [30] Case-control 483 ICD 34.47 Odds ratio Crude Low
Fitzpatrick, 2012 [31] Case-control 390 Histological Not reported Odds ratio Crude High
Ueno, 2014 [27] Cohort 65 Pathological Not reported Odds ratio Crude High
Open in a new tab

3.2. Effects of Exposure

Figure 2 presented the association between smoking and the PAS. Based on the random effect model, the estimated OR of the risk of PAS associated with smoking was 1.21 (95% CI: 1.02, 1.41; I2 = 4.7%). The finding of Farquhar's study [29] was reported among primiparous and multiparous, separately.

Figure 2.

Figure 2

Open in a new tab

Forest plot of the smoking and placenta accreta spectrum.

3.3. Publication Bias

Publication bias was carried out using Begg's and Egger's tests. The p values for Begg's and Egger's regression were 0.656 and 0.439, respectively. Evidence of publication bias was not seen among studies showing the association between smoking and PAS in Figure 3.

Figure 3.

Figure 3

Open in a new tab

Funnel plot of the smoking and placenta accreta spectrum.

3.4. Subgroup Analysis

Subgroup analysis was conducted based on study design, and the result showed that the association between smoking and PAS among cohort studies was significant 1.35 (95% CI: 1.15, 1.55; I2 = 0.0%), but this association among case-control studies was not significant 0.83 (95% CI: 0.47, 1.19; I2 = 0.0%). In addition, there was no significant association between smoking and PAS based on crude/adjust form (Table 2).

Table 2.

Results of subgroup analysis of the maternal smoking and placenta accreta spectrum based on study design and adjust/crude form for control of the counfounding variables.

Subgroups No. of studies OR (95% CI) I 2
Study design
 Case-control 4 0.83 (0.47, 1.19) 0.0%
 Cohort 10 1.35 (1.15, 1.55) 0.0%
Adjust/crude form
 Adjust analysis 6 1.11 (0.74, 1.49) 32.1%
 Crude analysis 8 1.29 (1.0, 1.58) 0.0%
Open in a new tab

3.5. Quality of the Studies

According to the NOS, 12 studies were high quality and 2 studies were low quality (Table 1).

4. Discussion

To the best of our knowledge, this is the first meta-analysis that reports the association between maternal smoking and the risk of PAS based on observational studies. Our findings reported that maternal smoking is a risk factor for the PAS. There was no heterogeneity among studies that reported an association between smoking and the PAS.

A meta-analysis was conducted in 2020 by Iacovelli et al. [32]. They reported that current smoking is not a risk factor for abnormally invasive placenta (OR = 1.13; 95% CI: 0.88, 1.47). They searched PubMed, Embase, and CINAHL databases with the design of case-control, case reports, and case series. However, they did not include all observational studies in the meta-analysis, and this can lead to bias among the results.

The rate of placenta accreta was reported from 0.001% to 0.9% of deliveries [33]. The incidence of placenta accreta has increased 10-fold in the past 50 years that probably resulted from the elevated cesarean section rate [34]. Advanced maternal age, uterine anomalies, and previous uterine scar appear to work synergistically to increase the risk of placenta accreta [35].

The characteristics and consequences of the patient are different in the subgroups of the accreta placenta spectrum, and women with the placenta increta and percreta have a high risk of morbidity and surgical mortality [22].

Elevated first-trimester serum placental growth factor (PIGF) was significantly associated with placenta accreta, indicating the potential role of PIGF in identifying high-risk pregnancies for placenta accreta [19].

Several studies have shown that smoking causes hypercoagulability and increased risk of thrombosis, and during pregnancy, due to physiological adaptation, the hemostatic system presents as a relatively hypercoagulable state with decreased anticoagulation function; however, studies in women with PAS have shown that they have hypocoagulability and hyperfibrinolysis [36]; therefore, the mechanism of the association between smoking and the PAS is unknown. However, the systemic inflammation induced by air pollution affects female genital tract damage, including damage to the endometrial and myometrium epithelium, and leads to poor decidualization [37, 38]. Another study showed that exposure to an air pollutant (PM2.5) was associated with placenta inflammation [39]. Therefore, it seems that pollutant-induced inflammation during pregnancy could also cause inflammation in the endometrium, leading to the PAS [40].

According to Tsuji et al., cadmium and lead levels in pregnant women with PAS were higher than normal pregnancies, and it is possible that increased cadmium levels play a role in the pathogenesis of PAS [20]. Smoking can also increase cadmium levels in the blood [41]. However, further studies are needed to substantiate this hypothesis because cadmium and lead levels were also higher in women with PAS without a history of smoking than in women with normal pregnancies [20].

4.1. Limitations

This study has some limitations. In our meta-analysis, diagnosis of PAS was most by clinicians, and pathology reports were not obtained from all cases. Therefore, most of the PAS cases in this study were clinically diagnosed. In addition, some of the included studies in our meta-analysis adjusted for confounding variables. This was another limitation of this study. Also, all studies did not investigate the effect of smoking on the PAS in trimesters of pregnancy, separately. Therefore, we did not conduct a subgroup analysis based on time smoke use during pregnancy.

4.2. Strength points

One of the strengths of this study is the homogeneity of the studies included in the meta-analysis and their high quality; also, the present meta-analysis with 3,892,832 participants reported that maternal smoking is a risk factor for the PAS.

5. Conclusion

PAS is becoming increasingly common and is associated with significant morbidity and mortality. Knowledge of risk factors can help prevent and diagnose early. Our results suggested that maternal smoking is a risk factor for the PAS; also, there was no heterogeneity among studies that reported an association between smoking and the PAS.

Acknowledgments

The protocol of this study was supported by the Hamadan University of Medical Sciences with code 140102271360 and ethical code IR.UMSHA.REC.1401.025.

Abbreviations

PAS:

Placenta accreta spectrum

NOS:

Newcastle-Ottawa Scale

OR:

Odds ratio

CI:

Confidence interval

PRISMA:

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PIGF:

Placental growth factor.

Data Availability

Access to data is possible with permission from the responsible author.

Conflicts of Interest

The authors declared that there was no conflict of interest.

References

  • 1.Givens M., Einerson B. D., Allshouse A. A., et al. Trends in unplanned peripartum hysterectomy in the United States, 2009–2020. Obstetrics & Gynecology . 2022;139(3):449–451. doi: 10.1097/AOG.0000000000004673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wright J. D., Pri-Paz S., Herzog T. J., et al. Predictors of massive blood loss in women with placenta accreta. American journal of obstetrics and gynecology . 2011;205(1):p. 38.e1. doi: 10.1016/j.ajog.2011.01.040. [DOI] [PubMed] [Google Scholar]
  • 3.Kyozuka H., Yamaguchi A., Suzuki D., et al. Risk factors for placenta accreta spectrum: findings from the Japan environment and Children’s study. BMC pregnancy and childbirth . 2019;19(1):1–7. doi: 10.1186/s12884-019-2608-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ghezzi C. L. A., Silva C. K., Casagrande A. S., Westphalen S. S., Salazar C. C., Vettorazzi J. Diagnostic performance of radiologists with different levels of experience in the interpretation of MRI of the placenta accreta spectrum disorder. The British journal of radiology . 2021;94(1128):p. 20210827. doi: 10.1259/bjr.20210827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Piñas Carrillo A., Chandraharan E. Placenta accreta spectrum: risk factors, diagnosis and management with special reference to the triple P procedure. Women's Health . 2019;15:p. 174550651987808. doi: 10.1177/1745506519878081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Pagani G., Cali G., Acharya G., et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. Acta obstetricia et gynecologica Scandinavica . 2018;97(1):25–37. doi: 10.1111/aogs.13238. [DOI] [PubMed] [Google Scholar]
  • 7.Jenabi E., Salimi Z., Salehi A. M., Khazaei S. The environmental risk factors prior to conception associated with placenta accreta spectrum: An umbrella review. Journal of Gynecology Obstetrics and Human Reproduction . 2022;51(7, article 102406) doi: 10.1016/j.jogoh.2022.102406. [DOI] [PubMed] [Google Scholar]
  • 8.Wang W., Fan D., Wang J., et al. Association between hypertensive disorders complicating pregnancy and risk of placenta accreta: a meta-analysis and systematic review. Hypertension in pregnancy . 2018;37(3):168–174. doi: 10.1080/10641955.2018.1498880. [DOI] [PubMed] [Google Scholar]
  • 9.Rafiee F., Beiki S. Assess the potential interventional radiology (IR) in improving the result of women undergoing surgery: systematic review and meta-analysis. International Journal of Pharmaceutical Research . 2020;12(3):p. 1328. [Google Scholar]
  • 10.Carusi D. A. The placenta accreta spectrum: epidemiology and risk factors. Clinical Obstetrics and Gynecology . 2018;61(4):733–742. doi: 10.1097/GRF.0000000000000391. [DOI] [PubMed] [Google Scholar]
  • 11.Movahed S., Tabrizi F. V., Pahlavani N., et al. Comprehensive assessment of nutritional status and nutritional-related complications in newly diagnosed esophageal cancer patients: a cross-sectional study. Clinical Nutrition . 2021;40(6):4449–4455. doi: 10.1016/j.clnu.2021.01.003. [DOI] [PubMed] [Google Scholar]
  • 12.Mansouri M., Pahlavani N., Sharifi F., et al. Dairy consumption in relation to hypertension among a large population of university students: the MEPHASOUS study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. . 2020;Volume 13:1633–1642. doi: 10.2147/DMSO.S248592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Shobeiri F., Jenabi E. Smoking and placenta previa: a meta-analysis. The journal of maternal-fetal & neonatal medicine . 2017;30(24):2985–2990. doi: 10.1080/14767058.2016.1271405. [DOI] [PubMed] [Google Scholar]
  • 14.Shobeiri F., Masoumi S. Z., Jenabi E. The association between maternal smoking and placenta abruption: a meta-analysis. The Journal of Maternal-Fetal & Neonatal Medicine . 2017;30(16):1963–1967. doi: 10.1080/14767058.2016.1235694. [DOI] [PubMed] [Google Scholar]
  • 15.Wells G. A., Shea B., O’Connell D., et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses . Oxford: 2000. [Google Scholar]
  • 16.Cumpston M., Li T., Page M. J., et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane database of systematic reviews . 2019;10, article ED000142 doi: 10.1002/14651858.ED000142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Egger M., Smith G. D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ . 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Begg C. B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics . 1994;50(4):p. 1088. doi: 10.2307/2533446. [DOI] [PubMed] [Google Scholar]
  • 19.Wang F., Zhang L., Zhang F., Wang J., Wang Y., Man D. First trimester serum PIGF is associated with placenta accreta. Placenta . 2020;101:39–44. doi: 10.1016/j.placenta.2020.08.023. [DOI] [PubMed] [Google Scholar]
  • 20.Tsuji M., Shibata E., Askew D. J., et al. Associations between metal concentrations in whole blood and placenta previa and placenta accreta: the Japan Environment and Children’s Study (JECS) Environmental health and preventive medicine . 2019;24(1):1–10. doi: 10.1186/s12199-019-0795-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Svanvik T., Jacobsson A. K., Carlsson Y. Prenatal detection of placenta previa and placenta accreta spectrum: evaluation of the routine mid-pregnancy obstetric ultrasound screening between 2013 and 2017. International Journal of Gynecology & Obstetrics . 2022;157(3):647–653. doi: 10.1002/ijgo.13876. [DOI] [PubMed] [Google Scholar]
  • 22.Matsuzaki S., Mandelbaum R. S., Sangara R. N., et al. Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States. American journal of obstetrics and gynecology . 2021;225(5, article e38):534.e1–534.e38. doi: 10.1016/j.ajog.2021.04.233. [DOI] [PubMed] [Google Scholar]
  • 23.Jauniaux E., Dimitrova I., Kenyon N., et al. Impact of placenta previa with placenta accreta spectrum disorder on fetal growth. Ultrasound in Obstetrics & Gynecology . 2019;54(5):643–649. doi: 10.1002/uog.20244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Eshkoli T., Weintraub A. Y., Sergienko R., Sheiner E. Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births. American journal of obstetrics and gynecology . 2013;208(3):p. 219.e1. doi: 10.1016/j.ajog.2012.12.037. [DOI] [PubMed] [Google Scholar]
  • 25.Bowman Z. S., Eller A. G., Bardsley T. R., Greene T., Varner M. W., Silver R. M. Risk factors for placenta accreta: a large prospective cohort. American journal of perinatology . 2014;31(9):799–804. doi: 10.1055/s-0033-1361833. [DOI] [PubMed] [Google Scholar]
  • 26.Upson K., Silver R. M., Greene R., Lutomski J., Holt V. L. Placenta accreta and maternal morbidity in the Republic of Ireland, 2005–2010. The Journal of Maternal-Fetal & Neonatal Medicine . 2014;27(1):24–29. doi: 10.3109/14767058.2013.799654. [DOI] [PubMed] [Google Scholar]
  • 27.Ueno Y., Kitajima K., Kawakami F., et al. Novel MRI finding for diagnosis of invasive placenta praevia: evaluation of findings for 65 patients using clinical and histopathological correlations. European radiology . 2014;24(4):881–888. doi: 10.1007/s00330-013-3076-7. [DOI] [PubMed] [Google Scholar]
  • 28.Usta I. M., Hobeika E. M., Musa A. A. A., Gabriel G. E., Nassar A. H. Placenta previa-accreta: risk factors and complications. American journal of obstetrics and gynecology . 2005;193(3):1045–1049. doi: 10.1016/j.ajog.2005.06.037. [DOI] [PubMed] [Google Scholar]
  • 29.Farquhar C. M., Li Z., Lensen S., et al. Incidence, risk factors and perinatal outcomes for placenta accreta in Australia and New Zealand: a case–control study. BMJ Open . 2017;7(10, article e017713) doi: 10.1136/bmjopen-2017-017713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Klar M., Laub M., Schulte-Moenting J., Proempeler H., Kunze M. Clinical risk factors for complete and partial placental retention–a case-control study. Journal of perinatal medicine . 2013;41(5):529–534. doi: 10.1515/jpm-2012-0260. [DOI] [PubMed] [Google Scholar]
  • 31.Fitzpatrick K. E., Sellers S., Spark P., Kurinczuk J. J., Brocklehurst P., Knight M. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PloS one . 2012;7(12, article e52893) doi: 10.1371/journal.pone.0052893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Iacovelli A., Liberati M., Khalil A., et al. Risk factors for abnormally invasive placenta: a systematic review and meta-analysis. The Journal of Maternal-Fetal & Neonatal Medicine . 2020;33(3):471–481. doi: 10.1080/14767058.2018.1493453. [DOI] [PubMed] [Google Scholar]
  • 33.Gielchinsky Y., Rojansky N., Fasouliotis S., Ezra Y. Placenta accreta--summary of 10 years: a survey of 310 cases. Placenta . 2002;23(2-3):210–214. doi: 10.1053/plac.2001.0764. [DOI] [PubMed] [Google Scholar]
  • 34.Practice C. O., American college of obstetricians and gynecologists ACOG committee opinion. Placenta accreta. Number 266. International journal of gynaecology and obstetrics . 2002;77(1):77–78. doi: 10.1016/s0020-7292(02)80003-0. [DOI] [PubMed] [Google Scholar]
  • 35.Lachman E., Mali A., Gino G., Burstein M., Stark M. Placenta accreta with placenta previa after previous cesarean sections--a growing danger in modern obstetrics. Harefuah . 2000;138(8):628–631. [PubMed] [Google Scholar]
  • 36.Guo Z., Han X., Zhang H., Zheng W., Yang H., Ma J. Association between pre-delivery coagulation indicators and invasive placenta accreta spectrum. Clinical and Applied Thrombosis/Hemostasis . 2022;28:p. 107602962110705. doi: 10.1177/10760296211070580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Van den Hooven E. H., de Kluizenaar Y., Pierik F. H., et al. Chronic air pollution exposure during pregnancy and maternal and fetal C-reactive protein levels: the generation R study. Environmental health perspectives . 2012;120(5):746–751. doi: 10.1289/ehp.1104345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lee P.-C., Talbott E. O., Roberts J. M., Catov J. M., Sharma R. K., Ritz B. Particulate air pollution exposure and C-reactive protein during early pregnancy. Epidemiology . 2011;22(4):524–531. doi: 10.1097/EDE.0b013e31821c6c58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.de Melo J. O., Soto S. F., Katayama I. A., et al. Inhalation of fine particulate matter during pregnancy increased IL-4 cytokine levels in the fetal portion of the placenta. Toxicology letters . 2015;232(2):475–480. doi: 10.1016/j.toxlet.2014.12.001. [DOI] [PubMed] [Google Scholar]
  • 40.Michikawa T., Morokuma S., Yamazaki S., Fukushima K., Kato K., Nitta H. Exposure to air pollutants during the early weeks of pregnancy, and placenta praevia and placenta accreta in the western part of Japan. Environment international . 2016;92-93:464–470. doi: 10.1016/j.envint.2016.04.037. [DOI] [PubMed] [Google Scholar]
  • 41.Fagerberg B., Barregard L. Review of cadmium exposure and smoking-independent effects on atherosclerotic cardiovascular disease in the general population. Journal of Internal Medicine . 2021;290(6):1153–1179. doi: 10.1111/joim.13350. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Access to data is possible with permission from the responsible author.

Articles from BioMed Research International are provided here courtesy of Wiley

RESOURCES